http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
- 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
- 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
RISS 인기검색어
- 검색키워드
- 저자 : ( Kofi Asomaning ) (검색결과 2 건)
- 무료
- 기관 내 무료
- 유료
-
( Eun Mi Chun ),( Mi Sun Lee ),( Kofi Asomaning ),( Rebecca Heist ),( Lii Su ),( David C Christiani ) 대한결핵 및 호흡기학회 2014 대한결핵 및 호흡기학회 추계학술대회 초록집 Vol.118 No.-
Background: Epidemiologic studies have been shown that the use of chemopreventive drugs may decrease cancer risk. Therefore, we aimed to investigate the effects of aspirin, NSAIDs, and statins use for reduced risk of lung cancer. We further examined whether genetic polymorphisms modify these effects. Methods: The study population consisted of 1,582 lung cancer patients and 816 controls from the Massachusetts General Hospital. SNPs were assessed in genes involved in phase II metabolism (GSTs, NAT2, EPHX, and NQO1), DNA repair (ERCC1, ERCC2, and XRCC1), DNA methylation (MTHFR C677T and A1298C), and angiogenesis (VEGF +936C>T, -460T>C, and +405G>C) pathways. Results: We used logistic regression to estimate the odds ratios (OR),and after adjustment for covariates, the use of statins and aspirin were significantly associated with reduced risk of lung cancer [OR 0.74, 95% confidence interval (CI) 0.56 to 0.97 for statins and OR 0.36, 95% CI 0.27 to 0.47 for aspirin, respectively], whereas an inverse association was seen with NSAIDs. Significant modifying effects were found by NAD(P)H quinine oxidoreductase (NQO1) gene polymorphisms with the use of statins (OR 0.57, 95% CI 0.40 to 0.80 for CC versus OR 1.21, 95% CI 0.74 to 1.99 for CT or TT, P = 0.03) and by glutathione S-transferases (GSTP1) with aspirin use (OR 0.23, 95% CI 0.15 to 0.35 for AA versus OR 0.46, 95% CI 0.32 to 0.67 for AG or GG, P = 0.04). Conclusions: Our results indicate that statins and aspirin use may attenuate the risk of lung cancer and genetic polymorphism may modify these associations. Key words: chemoprevention, genetic polymorphism, lung cancer, pharmacogenetics
-
( Eun Mi Chun ),( Mi Sun Lee ),( Kofi Asomaning ),( Rebecca Heist ),( Lii Su ),( David C Christiani ) 대한내과학회 2014 대한내과학회 추계학술대회 Vol.2014 No.1
Background: Epidemiologic studies have been shown that the use of chemopreventive drugs may decrease cancer risk. Therefore, we aimed to investigate the effects of aspirin, NSAIDs, and statins use for reduced risk of lung cancer. We further examined whether genetic polymorphisms modify these effects. Methods: The study population consisted of 1,582 lung cancer patients and 816 controls from the Massachusetts General Hospital. SNPs were assessed in genes involved in phase II metabolism (GSTs, NAT2, EPHX, and NQO1), DNA repair (ERCC1, ERCC2, and XRCC1), DNA methylation (MTHFR C677T and A1298C), and angiogenesis (VEGF +936C>T, -460T>C, and +405G>C) pathways. Results: We used logistic regression to estimate the odds ratios (OR),and after adjustmentfor covariates, the use of statins and aspirin were signifi cantly associated with reduced risk of lung cancer [OR 0.74, 95% confi dence interval (CI) 0.56 to 0.97 for statins and OR 0.36, 95% CI 0.27 to 0.47 for aspirin, respectively], whereas an inverse association was seen with NSAIDs. Signifi cant modifying effects were found by NAD( P)H quinine oxidoreductase (NQO1) gene polymorphisms with the use of statins (OR 0.57, 95% CI 0.40 to 0.80 for CC versus OR 1.21, 95% CI 0.74 to 1.99 for CT or TT, P = 0.03) and by glutathione S-transferases (GSTP1) with aspirin use (OR 0.23, 95% CI 0.15 to 0.35 for AA versus OR 0.46, 95% CI 0.32 to 0.67 for AG or GG, P = 0.04).Conclusions: Our results indicate that statins and aspirin use may attenuate the risk of lung cancer and genetic polymorphism may modify these associations.
연관 검색어 추천
이 검색어로 많이 본 자료
활용도 높은 자료
